| UNITED STATES | |||||
| SECURITIES AND EXCHANGE COMMISSION | |||||
| Washington, D.C. 20549 | |||||
| FORM 12b-25 | |||||
| NOTIFICATION OF LATE FILING | |||||
| (Check one): | ¨ Form 10-K | ¨ Form 20-F | ¨ Form 11-K | ý Form 10-Q | ¨ Form 10-D | ||||||||||||
¨ Form N-CSR | |||||||||||||||||
| For Period Ended: | September 30, 2020 | ||||||||||||||||
¨ Transition Report on Form 10-K | ||||||||
¨ Transition Report on Form 20-F | ||||||||
¨ Transition Report on Form 11-K | ||||||||
¨ Transition Report on Form 10-Q | ||||||||
¨ Transition Report on Form N-SAR | ||||||||
| For the Transition Period Ended: | ||||||||
| Read Instructions (on back page) Before Preparing Form. Please Print or Type. | ||||||||
| Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. | ||||||||
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION
| PDL BIOPHARMA, INC. | ||
| Full Name of Registrant | ||
| N/A | ||
| Former Name if Applicable | ||
| 932 SOUTHWOOD BLVD. | ||
Address of Principal Executive Office (Street and Number) | ||
| INCLINE VILLAGE, NEVADA 89451 | ||
| City, State and Zip Code | ||
PART II - RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
| ý | (a) | The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense | ||||||
| (b) | The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and | |||||||
| (c) | The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. | |||||||
1
PART III - NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
PDL BioPharma, Inc. (the “Registrant”) is unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 (the “Form 10-Q”) on the prescribed due date. The Registrant needs additional time to complete its quarterly financial statements, including disclosures relating to the implementation of the liquidation basis of accounting (“Liquidation Basis”) as of September 1, 2020. The reasons causing the inability to timely file could not be eliminated by the Registrant without unreasonable effort or expense, and the Registrant currently intends to file the Form 10-Q no later than the fifth calendar day following the prescribed due date.
PART IV - OTHER INFORMATION
| (1) | Name and telephone number of person to contact in regard to this notification | |||||||||||||||||||
| Edward A. Imbrogno | (775) | 832-8500 | ||||||||||||||||||
| (Name) | (Area Code) | (Telephone Number) | ||||||||||||||||||
| (2) | Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). | |||||||||||||||||||
ý Yes | ¨ No | |||||||||||||||||||
| (3) | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? | |||||||||||||||||||
ý Yes | ¨ No | |||||||||||||||||||
| If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made | ||||||||||||||||||||
As a result of the approval of the Company’s stockholders on August 19, 2020 to pursue dissolution of the Company pursuant to a plan of dissolution, the Company’s basis of accounting transitioned, effective September 1, 2020, from the going concern basis of accounting to the Liquidation Basis in accordance with Generally Accepted Accounting Principles (“GAAP”) of the United States. Under the Liquidation Basis, all assets are stated at their estimated liquidation value, contractual liabilities are measured in accordance with applicable GAAP and all other liabilities are stated at their estimated settlement amounts over the remaining estimated liquidation period.
| PDL BIOPHARMA, INC. | ||||||||||||||||||||
| (Name of Registrant as Specified in Charter) | ||||||||||||||||||||
| has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized. | ||||||||||||||||||||
| Date | November 9, 2020 | By | /s/ Edward A. Imbrogno | |||||||||||||||||
| Edward A. Imbrogno | ||||||||||||||||||||
| Vice President and Chief Financial Officer | ||||||||||||||||||||
INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.
| ATTENTION | ||
| Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001). | ||
2